145 related articles for article (PubMed ID: 32416521)
1. Nanoparticle mediated codelivery of nifuratel and doxorubicin for synergistic anticancer therapy through STAT3 inhibition.
Zheng H; Chen Z; Cai A; Lin X; Jiang X; Zhou B; Wang J; Yao Q; Chen R; Kou L
Colloids Surf B Biointerfaces; 2020 Sep; 193():111109. PubMed ID: 32416521
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterisation and in vitro and in vivo evaluation of CD44-targeted chondroitin sulphate-conjugated doxorubicin PLGA nanoparticles.
Liu P; Chen N; Yan L; Gao F; Ji D; Zhang S; Zhang L; Li Y; Xiao Y
Carbohydr Polym; 2019 Jun; 213():17-26. PubMed ID: 30879657
[TBL] [Abstract][Full Text] [Related]
4. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.
Su WP; Cheng FY; Shieh DB; Yeh CS; Su WC
Int J Nanomedicine; 2012; 7():4269-83. PubMed ID: 22904633
[TBL] [Abstract][Full Text] [Related]
5. Novel "Carrier-Free" Nanofiber Codelivery Systems with the Synergistic Antitumor Effect of Paclitaxel and Tetrandrine through the Enhancement of Mitochondrial Apoptosis.
Li X; Yu N; Li J; Bai J; Ding D; Tang Q; Xu H
ACS Appl Mater Interfaces; 2020 Mar; 12(9):10096-10106. PubMed ID: 32027119
[TBL] [Abstract][Full Text] [Related]
6. A novel nanoformulation of parthenolide coated with polydopamine shows selective cytotoxicity and induces apoptosis in gastric cancer cells.
Karimian Ensaf P; Goodarzi MT; Homayouni Tabrizi M; Neamati A; Hosseinyzadeh SS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4435-4445. PubMed ID: 38108837
[TBL] [Abstract][Full Text] [Related]
7. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound.
Wang J; Wang F; Li X; Zhou Y; Wang H; Zhang Y
Colloids Surf B Biointerfaces; 2019 May; 177():425-432. PubMed ID: 30798063
[TBL] [Abstract][Full Text] [Related]
8. Self-assembled nanoparticles of reduction-sensitive poly (lactic-co-glycolic acid)-conjugated chondroitin sulfate A for doxorubicin delivery: preparation, characterization and evaluation.
Wang XF; Ren J; He HQ; Liang L; Xie X; Li ZX; Zhao JG; Yu JM
Pharm Dev Technol; 2019 Jul; 24(6):794-802. PubMed ID: 30907676
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
10. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
[TBL] [Abstract][Full Text] [Related]
11. PLGA based particles as "drug reservoir" for antitumor drug delivery: characterization and cytotoxicity studies.
Chronopoulou L; Domenici F; Giantulli S; Brasili F; D'Errico C; Tsaouli G; Tortorella E; Bordi F; Morrone S; Palocci C; Silvestri I
Colloids Surf B Biointerfaces; 2019 Aug; 180():495-502. PubMed ID: 31103709
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment.
Chevalier MT; Garona J; Sobol NT; Farina HG; Alonso DF; Álvarez VA
Nanomedicine (Lond); 2018 Nov; 13(22):2835-2849. PubMed ID: 30430901
[TBL] [Abstract][Full Text] [Related]
14. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of Doxorubicin and D-α-Tocopherol Polyethylene Glycol 1000 Succinate by Magnetic Nanoparticles.
Metin E; Mutlu P; Gündüz U
Anticancer Agents Med Chem; 2018; 18(8):1138-1147. PubMed ID: 29532763
[TBL] [Abstract][Full Text] [Related]
16. Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity.
Wang J; Zhang G; Dai C; Gao X; Wu J; Shen L; Chen Z; Liu P
J Int Med Res; 2017 Feb; 45(1):220-230. PubMed ID: 28222632
[TBL] [Abstract][Full Text] [Related]
17. Development and optimization of doxorubicin loaded poly(lactic-co-glycolic acid) nanobubbles for drug delivery into HeLa cells.
Deng L; Li L; Yang H; Li L; Zhao F; Wu C; Liu Y
J Nanosci Nanotechnol; 2014 Apr; 14(4):2947-54. PubMed ID: 24734715
[TBL] [Abstract][Full Text] [Related]
18. PLGA nanoparticle-based docetaxel/LY294002 drug delivery system enhances antitumor activities against gastric cancer.
Cai J; Qian K; Zuo X; Yue W; Bian Y; Yang J; Wei J; Zhao W; Qian H; Liu B
J Biomater Appl; 2019 May; 33(10):1394-1406. PubMed ID: 30952195
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro.
Sun JH; Ye C; Bai EH; Zhang LL; Huo SJ; Yu HH; Xiang SY; Yu SQ
Nanotechnology; 2019 Feb; 30(8):085101. PubMed ID: 30523865
[TBL] [Abstract][Full Text] [Related]
20. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
Eivazi N; Rahmani R; Paknejad M
Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]